Patents Represented by Attorney, Agent or Law Firm Pamela J. Sherwood
  • Patent number: 6881406
    Abstract: Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra?, and integrin ?4?7?, express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity. An advantage of the invention is the selectivity for systemic memory T cells, without affecting native T cells or intestinal memory T cells.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: April 19, 2005
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Millennium Pharmaceuticals, Inc.
    Inventors: Eugene C. Butcher, James J. Campbell, Lijun Wu, James B. Rottman
  • Patent number: 6876930
    Abstract: There is a pressing need for computer-implemented tools that can summarize and present the enormous amounts of public literature to facilitate analysis of gene expression data. The present invention provides techniques and systems for efficiently integrating public literature regarding gene function with data from gene expression profiling experiments. Information from literature databases relating to a particular set of DNA sequences of known expression pattern is retrieved, processed, cross-referenced and viewed to provide further information about a particular DNA sequence to facilitate its identification as a candidate gene.
    Type: Grant
    Filed: March 4, 2002
    Date of Patent: April 5, 2005
    Assignee: AGY Therapeutics, Inc.
    Inventors: Joseph Murray, Donna Hendrix, Daniel J Chin
  • Patent number: 6830925
    Abstract: Methods for isolating CaMK-X1 genes are provided. The CaMK-X1nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: December 14, 2004
    Assignee: QLT Inc.
    Inventors: Thillainathan Yoganathan, Allen Delaney
  • Patent number: 6821524
    Abstract: Cosmetic skin care compositions containing thymosin beta 4 are provided. The compositions improve the appearance of aged or damaged skin.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: November 23, 2004
    Assignee: Jan Marini Skin Research, Inc.
    Inventor: Jan L. Marini
  • Patent number: 6812037
    Abstract: Antimitotic terpenoid compounds including sarcodictyin A and as eleutherobin may be obtained from organisms of the order Gorgonacea. Methods of preparing such compounds provided, as are novel antimitotic diterpene compounds having formula (I).
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: November 2, 2004
    Assignee: The University of British Columbia
    Inventors: Raymond J. Andersen, Michel Roberge, Bruno Cinel
  • Patent number: 6780604
    Abstract: Nucleic acid compositions encoding a pro-apoptotic protein, Bok (Bcl-2-related ovarian killer) are identified. Bok has conserved Bcl-2 homology domains 1, 2 and 3 and a C-terminal transmembrane region present in other Bcl-2 related proteins, but lacks the BH4 domain found only in anti-apoptotic Bcl-2 proteins. Over-expression of Bok induces apoptosis. Cell killing induced by Bok is suppressed by co-expression with selective anti-apoptotic Bcl-2 proteins. Bok is highly expressed in the ovary, testis and uterus, particularly in granulosa cells, the cell type that undergoes apoptosis during follicle atresia. Identification of Bok as a new pro-apoptotic protein with wide tissue distribution and hetero-dimerization properties facilitates elucidation of apoptosis mechanisms in reproductive and other tissues, and provides a means for manipulating apoptosis.
    Type: Grant
    Filed: October 4, 2001
    Date of Patent: August 24, 2004
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Aaron J. W. Hsueh, Sheau Yu Hsu
  • Patent number: 6763307
    Abstract: Clinical patient tissue samples are classified according to the physiological status of cells present in the sample. In some embodiments of the invention, such cells are classified according to their ability to respond to therapeutic agents and treatments. In other embodiments, the cells or tissue samples are classified according to their status with respect to the activity of pathways of interest. The information thus derived is useful in prognosis and diagnosis, and can further be used develop surrogate markers for disease states, and to investigate the effect of genetic polymorphisms in the responsiveness and state of cells involved in disease.
    Type: Grant
    Filed: September 13, 2001
    Date of Patent: July 13, 2004
    Assignee: BioSeek, Inc.
    Inventors: Ellen L. Berg, Eugene C. Butcher, Jennifer Melrose
  • Patent number: 6761883
    Abstract: A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided into specific myeloid progenitor subsets, including a common myeloid progenitor cells (CMP), megakaryocyte/erythroid progenitor cells (MEP) and granulocyte/monocyte lineage progenitor (GMP). Methods are provided for the isolation and culture of these subpopulations. The CMP population gives rise to all myeloid lineages, and can give rise to the two additional and isolatable progenitor populations that are exclusively committed to either the erythroid/megakaryocytic or myelomonocytic lineages. The cell enrichment methods employ reagents that specifically recognize Thy-1; and IL-7R&agr;, in conjunction with other markers expressed on lineage committed cells.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: July 13, 2004
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, David Jeffrey Traver, Koichi Akashi, Markus Gabriel Manz, Toshihiro Miyamoto
  • Patent number: 6753153
    Abstract: The differential expression of marker proteins in a targeted population provides a means of identifying and isolating cells. A population of cells associated with the regeneration of pancreatic islets is shown to express certain proteins, including the cell surface proteins ErbB2, ErbB3, and ErbB4; and the nuclear protein Msx-2. Populations of isolated pancreatic islet progenitor cells find use in screening assays, to characterize genes involved in islet development and regulation, and in transplantation to provide a recipient with pancreatic islet functions.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: June 22, 2004
    Assignee: The Scripps Research Institute
    Inventors: Nora Sarvetnick, Marcie Kritzik
  • Patent number: 6753158
    Abstract: A yeast homologue of mammalian DNA ligase IV is provided and a role for DNA ligase IV established in the Ku-associated DNA repair pathway. Additionally interactions between DNA ligase IV and XRCC4, and interaction between XRCC4 and DNA-PKcs/Ku are established, providing for assays for agents which modulate such interactions and therefore cellular DNA repair activity. Such agents are useful in treatment of cancers, retroviral infections, immune system disorders and other conditions in which cellular DNA repair activity plays a role. Individuals with a predisposition to a disorder in which DNA repair plays a role may be diagnosed, by screening for the presence or absence of a defect in XRCC4 and/or DNA ligase IV activity.
    Type: Grant
    Filed: July 12, 1999
    Date of Patent: June 22, 2004
    Assignee: Kudos Pharmaceuticals Limited
    Inventors: Stephen Philip Jackson, Susan Elizabeth Critchlow
  • Patent number: 6737272
    Abstract: Nitric oxide synthase and nitric-oxide-related bioactivity are shown to be necessary and sufficient for activation of an oocyte during the process of fertilization. Methods are provided for the modulation of oocyte activation through modulation of nitric oxide levels. Oocyte activation is enhanced by the addition of nitric oxide synthase, nitric oxide synthase activators, nitric oxide donors, or other compounds that increase the nitric oxide levels of the oocyte during fertilization. The administration of NOS inhibitors is used to block oocyte activation, where contraception is desired.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: May 18, 2004
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Cornell Research Foundation, Inc.
    Inventors: Richard Kuo, Gregory Baxter, David Epel
  • Patent number: 6737241
    Abstract: Methods and compositions for screening for intracellular transdominant effector peptides and RNA molecules selected inside living cells from randomized pools are provided.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: May 18, 2004
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: Garry P. Nolan
  • Patent number: 6713078
    Abstract: Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: March 30, 2004
    Assignee: The Regents of the University of California
    Inventors: Robert I. Lehrer, Alan J. Waring, Alexander M. Cole, Teresa B. Hong
  • Patent number: 6709840
    Abstract: Isolated nucleic acid compositions and sequences of anergy associated genes are provided, including the novel GRAIL gene. Expression of these genes is upregulated during the early stages of induction of anergy. The murine GRAIL sequence is shown to attenuate IL-2 transcription in T cells during response to antigenic stimulation. The identification of genes involved in the induction of anergy is useful in the evaluation of the pathophysiology or immunotherapy of cancer, autoimmune disease, and transplant rejection. Genetic sequences involved in anergy induction are useful markers in the evaluation of specific immunotherapies. Functional characterization of genes involved in anergy induction allows the elucidation of the mechanism(s) of T cell anergy, including the transcriptional blockade of IL-2, which may be manipulated to regulate T cell responses in human disease.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: March 23, 2004
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Gregory Ford, Debra Bloom, C. Garrison Fathman
  • Patent number: 6709827
    Abstract: Mismatch Repair Detection (MRD), a novel method for DNA-variation detection, utilizes bacteria to detect mismatches by a change in expression of a marker gene. DNA fragments to be screened for variation are cloned into two MRD plasmids, and bacteria are transformed with heteroduplexes of these constructs. Resulting colonies express the marker gene in the absence of a mismatch, and lack expression in the presence of a mismatch. MRD is capable of detecting a single mismatch within 10 kb of DNA. In addition, MRD can analyze many fragments simultaneously, offering a powerful method for high-throughput genotyping and mutation detection.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: March 23, 2004
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California
    Inventors: David R. Cox, Malek Faham, Siamak Baharloo
  • Patent number: 6699983
    Abstract: Methods for isolating ILK genes are provided. The ILK nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.
    Type: Grant
    Filed: June 6, 2000
    Date of Patent: March 2, 2004
    Assignee: Sunnybrook Health Sciences Centre
    Inventors: Shoukat Dedhar, Greg Hannigan
  • Patent number: 6699279
    Abstract: An expandable space frame is manufactured by linking a plurality of flexible joints through spacing arms to form a closed structure. The spacing arms are sterically offset, linking the bottom of one joint to the top of the next joint in an stepwise fashion. The offset allows the frame to be collapsed with minimal steric hindrance between the centered joints. This lack of steric hindrance permits a very high ratio of the expansion to compression diameters for the frame. The space frame forms the basis for different types of stents. A spiral frame, or a series of individual frames are linked to each other to form a luminal stent, or are linked to longitudinal struts to form the support structure for a stent. The stents formed from the expandable space frame can be designed to have a number of additional features as set forth herein.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: March 2, 2004
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Walter J. Stevens, George S. Springer
  • Patent number: 6692736
    Abstract: Disclosed herein are replication-competent adenovirus vectors comprising co-transcribed first and second genes under transcriptional control of a heterologous, target cell-specific transcriptional regulatory element (TRE), wherein the second gene is under translational control of an internal ribosome entry site. Methods for the preparation and use of such vectors are also provided. The vectors provide target cell-specific virus replication in applications such as cancer therapy and gene therapy.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: February 17, 2004
    Assignee: Cell Genesys, Inc.
    Inventors: De-Chao Yu, Yuanhao Li, Andrew S. Little, Daniel R. Henderson
  • Patent number: 6686166
    Abstract: Specific genetic deletions are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: February 3, 2004
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
  • Patent number: 6676935
    Abstract: Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for treating neoplasia.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: January 13, 2004
    Assignee: Cell Genesys, Inc.
    Inventors: Daniel R. Henderson, Eric R. Schuur